As of today (2025-05-13), Mind Medicine's share price is $6.45.
Mind Medicine's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.13. Hence, Mind Medicine's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Mind Medicine's Price-to-Free-Cash-Flow or its related term are showing as below:
MNMD's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.405 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 12.50% per year.
During the past 5 years, Mind Medicine's highest 3-Year average Free Cash Flow per Share Growth Rate was 12.50% per year. The lowest was -7.30% per year. And the median was 2.60% per year.
Mind Medicine Price-to-Free-Cash-Flow Historical Data
The historical data trend for Mind Medicine's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mind Medicine's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Mind Medicine's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mind Medicine's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mind Medicine's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Mind Medicine's Price-to-Free-Cash-Flow falls into.
Mind Medicine's Share Price of today is $6.45. Mind Medicine's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Mind Medicine (NAS:MNMD) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Mind Medicine Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Mind Medicine's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNMD has been successfully added to your 